info@biomarkr.health
Pointing hand
Biomarkr
Immune Monitoring
For Biological Intelligence
Our Mission Is To:
Save 30M lives each year
OUR

Thesis

After more than a decade of engineering, Biomarkr has brought lab-grade biomarker measurement beyond centralized laboratories and into the hands of individuals. Immunoassay technology has been miniaturized onto a semiconductor chip and integrated into a palm-sized device, making repeatable biomarker measurement possible in minutes.

This creates a new measurement layer built on ease of use and repeatability. Personalized baselines can now be established, allowing biological change to be measured over time. Measurement shifts from isolated tests to longitudinal insight and recurring measurement cadence.

Additional biomarker panels will be introduced without changing the hardware. As measurement expands across biological systems, testing frequency increases and longitudinal datasets deepen, strengthening both insight and economics over time.

Personalized biomarker measurement in minutes. Baseline. Then track.

TECHNOLOGY

Hardware

We miniaturized a laboratory grade immunoassay onto a silicon photonic chip roughly the size of a fingernail. By collapsing the optics, fluidics, and detection into a solid-state format, we've achieved sensitivity that previously required expensive lab equipment, but without the bulky lasers, mechanical parts, or complex calibration. The platform works with microliter-scale samples, needs no specialized handling, and can test virtually any biomarker using standard immunoassay chemistry. It's essentially ELISA on a chip, manufactured at semiconductor scale with consumer-level economics.

This results in:

  • 10-40x cost reduction
  • Results in under 10 minutes
  • Useable at-home & point of care
  • Lab-grade accuracy
  • Biomarker agnostic; can test virtually any protein, hormone, or immune marker
  • Up to 32 biomarkers per test
TECHNOLOGY

Software

The Software: AI that Gets Smarter with Every Test

A single cytokine value is meaningless. Is IL-6 at 15 pg/mL good or bad? It depends on your baseline, age, stress, time of day, and dozens of other factors. Traditional labs give you one number with a population-wide "normal range" that can't predict your future. We're building personalized immune intelligence from high-frequency longitudinal data.

Our AI enables:

  • Personalized Baselines: Your first tests begin to establish your normal, not the average person's. We learn your patterns: circadian rhythms, stress response, exercise recovery. Every test after is measured against your unique baseline, detecting shifts days or weeks before symptoms.
  • Cytokine Signatures: Diseases create multi-dimensional patterns across biomarkers. Viral infections look different from autoimmune flares, which look different from cardiovascular inflammation. Machine learning models build longitudinal signatures from 5 cytokines simultaneously.
  • Personalized Predictions: With enough data, we predict instead of just measure. When will your next flare happen? Is this fatigue overtraining or early infection? Should you adjust medication this week? Models trained on millions of measurements make insightful predictions personalized to you.
  • Population-Level Insights: Weekly biomarker data across tens of thousands of people has never existed. What immune patterns precede Alzheimer's by years? Can we predict treatment response before patients start medication? What interventions reduce biological age? Access to this data will catalyze the largest advancements to healthcare since antibiotics.
  • Personalized Lifestyle and Nutrition Guidance: AI interprets ongoing biomarker trends to recommend data-driven adjustments in diet, activity, sleep, and supplements, helping individuals move beyond guesswork and over-supplementation by objectively measuring which interventions are beneficial, neutral, or unnecessary.
OUR

Team

Dylan Brownstein
Dylan Brownstein
CEO

Serial entrepreneur. Previously founded VC backed, AI-driven SaaS company and media company. Former investor at Karcher Ventures. Consulted for Google, Reddit, YMCA. Strengths in AI product development and go-to-market.

Dr. Reuven Duer
Dr. Reuven Duer, PhD
Chief Science Officer

Inventor of the Q-SENS platform. PhD in Physics from Technion. 15+ years leading medical device engineering teams. 22 patents. Led BARDA-funded prototype development.

Dr. Aren Giske
Dr. Aren Giske, MD
Chief Operations Officer

Twice-appointed medical director. Board Member at Kadlec Medical Center. Occupational and Environmental Medicine specialist. Deep expertise in clinical implementation and population health.

From Reactive
to Proactive

Q-SENS Device